1. Home
  2. MLYS vs GSM Comparison

MLYS vs GSM Comparison

Compare MLYS & GSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • GSM
  • Stock Information
  • Founded
  • MLYS 2019
  • GSM 2015
  • Country
  • MLYS United States
  • GSM United Kingdom
  • Employees
  • MLYS N/A
  • GSM N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • GSM Metal Mining
  • Sector
  • MLYS Health Care
  • GSM Basic Materials
  • Exchange
  • MLYS Nasdaq
  • GSM Nasdaq
  • Market Cap
  • MLYS 893.0M
  • GSM 739.5M
  • IPO Year
  • MLYS 2023
  • GSM N/A
  • Fundamental
  • Price
  • MLYS $14.61
  • GSM $3.71
  • Analyst Decision
  • MLYS Strong Buy
  • GSM Hold
  • Analyst Count
  • MLYS 3
  • GSM 1
  • Target Price
  • MLYS $33.00
  • GSM N/A
  • AVG Volume (30 Days)
  • MLYS 679.3K
  • GSM 901.3K
  • Earning Date
  • MLYS 05-12-2025
  • GSM 05-07-2025
  • Dividend Yield
  • MLYS N/A
  • GSM 1.65%
  • EPS Growth
  • MLYS N/A
  • GSM N/A
  • EPS
  • MLYS N/A
  • GSM N/A
  • Revenue
  • MLYS N/A
  • GSM $1,559,264,000.00
  • Revenue This Year
  • MLYS N/A
  • GSM N/A
  • Revenue Next Year
  • MLYS N/A
  • GSM $6.90
  • P/E Ratio
  • MLYS N/A
  • GSM N/A
  • Revenue Growth
  • MLYS N/A
  • GSM N/A
  • 52 Week Low
  • MLYS $8.24
  • GSM $2.97
  • 52 Week High
  • MLYS $18.38
  • GSM $6.19
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 61.10
  • GSM 50.68
  • Support Level
  • MLYS $14.03
  • GSM $3.04
  • Resistance Level
  • MLYS $15.79
  • GSM $3.62
  • Average True Range (ATR)
  • MLYS 0.93
  • GSM 0.14
  • MACD
  • MLYS 0.16
  • GSM 0.00
  • Stochastic Oscillator
  • MLYS 92.27
  • GSM 68.01

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About GSM Ferroglobe PLC

Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel and ductile iron foundry industries. The company's business segments include North America - Silicon; Europe - Manganese; Europe - Silicon; South Africa - Silicon and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.

Share on Social Networks: